Humacyte Q3 net loss narrows 11% year over year to $15.54 million
HUMA•Humacyte’s third-quarter 2026 net loss narrowed 11% year over year to $15.54 million, while revenue rose 37% to $1.03 million. Symvess revenue more than doubled sequentially to $1.02 million.
1. Quarterly results
Humacyte said its third-quarter 2026 net loss narrowed 11% year over year to $15.54 million, primarily due to lower research and development expenses. Total revenue climbed 37% to $1.03 million, and Symvess revenue more than doubled quarter over quarter to $1.02 million. The company expects fourth-quarter revenue to at least double sequentially.
2. Pipeline plans
Humacyte said a supplemental FDA application to add dialysis access as an approved ATEV indication remains planned for November 2026. A first-in-human Phase 2a study of CTEV in coronary artery bypass grafting began in November 2026.
